The whole cell vaccines include tumor cell-based vaccine which has poor immunogenicity and requires GM-CSF, dendritic cell-based vaccine which induces significant cell mediated anti-HER2 immune response, and autologous T cell-based vaccine which is an adoptive transfer of autologous HER2 specific T lymphocytes. Here, ERBB2 is linked to neoplasm.